Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
What safety, toxicity, or tolerability evidence is attached?
Normalized for positional visualization, not a replacement for the reported modified notation.
CYIQNCPLG
Original notation retained for interpretation and comparison.
CYIQNCPLG
Interpretation: Evidence should be compared across compatible peptide identities and peptidoforms. A sequence-only match may not be equivalent when terminal modifications, stereochemistry, cyclization, or cross-links differ.
CYIQNCPLGPolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
| Link | Method | Confidence | Match |
|---|---|---|---|
| Open |
| Feature | Positions | Interpretation | Link |
|---|---|---|---|
| Disulfide | 1-6 | 2.04 A SG-SG | Open |
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
Modeled net charge across common formulation and assay pH checkpoints.
Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.
Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.
Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.
Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.
A280 (1 g/L) ≈ 1.48 · 1,615 M⁻¹·cm⁻¹ with 1 disulfide
Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.85 % | Comparable | Oral bioavailability in rat · rat | Route: oral · bioavailability · F· Oral bioavailability in rat · Exact ChEMBL pref name OXYTOCIN · http... | Open |
| 2 | 0.007-0.07 % | Comparable | PepTherDia curated product PK field | Route: SL · 2 · Oxytocin · exact product name match · exact or normalized match | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 33.2 L | Comparable | Manual extraction from PubMed-indexed clinical PK abstract; two-compartment model after IV oxytocin · human · plasma | Route: intravenous | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Serum/plasma stability and protease stability evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.5 Hours 1800 seconds | Comparable | LC-MS/MS · mouse · C57BL/6J mice plasma | Route: SC · Dose/window: 10 ml/kg · Time: Time points postdose: 0.25 (OT only), 0.5, 1, 2, 4, 6, and 24 hours (6- and 24-hour sampling limited to PF1 o... · C57Bl/6J mice plasma protease · In Vivo | Open |
| 2 | 7.3 Hours 26280 seconds | Comparable | LC-MS/MS · mouse · C57BL/6J mice plasma | Route: SC · Dose/window: 20 mg/kg · Time: Serial blood samples were collected from each mouse via the retro-orbital sinus at the following time points... · C57Bl/6J mice plasma protease · In Vivo | Open |
| 3 | 0.12 Hours 432 seconds | Comparable | LC-MS/MS · rat · Wistar rats plasma | Route: IV · Dose/window: 0.1 mg/kg · Time: Time points postdose: 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours · Wistar rats plasma protease · In Vivo | Open |
Interpretation: In vitro stability, protease stability, and percent-remaining measurements are not collapsed into one value.
Reviewed observations retained without being collapsed into comparable values.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 21 mL/min/kg | Comparable | Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus dose · rat | Route: iv · clearance · CL· Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette... | Open |
| 2 | 7.87 mL/min | Comparable | curated therapeutic product PK entry | Route: Primary literature supports oxytocin clearance in the same quantitative range | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference link | Distribution Blood Brain Barrier Penetration | No reported alias CYIQNCPLGexact | 3 identity 3 evidence |
PubMed 10454085 | Persistence Half Life | No reported alias CYIQNCPLGexact | 2 identity 2 evidence |
PubMed 27217590 | Stability Serum Plasma Stability | No reported alias CYIQNCPLGexact | 2 identity 2 evidence |
PubMed 27217590 | Stability Serum Plasma Stability | No reported alias CYIQNCPLGexact | 1 identity 1 evidence |
PubMed 22186872 | Persistence Half Life | No reported alias CYIQNCPLGexact | 1 identity 1 evidence |
Reference link | Persistence Clearance | No reported alias CYIQNCPLGexact | 1 identity 1 evidence |
Reference link | Distribution Blood Brain Barrier Penetration | No reported alias CYIQNCPLGexact | 1 identity 1 evidence |
Reference link | Distribution Blood Brain Barrier Penetration | No reported alias CYIQNCPLGexact | 1 identity 1 evidence |
Reference link | Distribution Blood Brain Barrier Penetration | No reported alias CYIQNCPLGexact | 1 identity 1 evidence |
Reference link | Distribution Blood Brain Barrier Penetration | No reported alias CYIQNCPLGexact | 1 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0018730' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.
Features are shown only when a reported notation or topology record supports them.
Cysteine linkage reported between positions 1 and 6.
| Experimental structure match |
| experimental |
| 9 aa |
| Open | Experimental structure match | experimental | 9 aa |
Grouped composition is often more interpretable than a long amino-acid list.
The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~= 40 min ~= 2400 seconds | Comparable | Manual extraction from PubMed-indexed clinical PK abstract; plasma oxytocin sampling during labor-augmentation infusion · human · plasma | Route: intravenous infusion · Dose/window: labor augmentation infusion; 1 mU/min initial dose; 1 mU/min increments every 4... · Time: approximately 40 min after each dose step | Open |
The same three research-facing layers are used across ADMETatlas.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 30 % | Comparable | PepTherDia curated product PK field · plasma protein | Route: IV, IM · 2 · Oxytocin · exact product name match · exact or normalized match | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.00815 mL/g | Comparable | Intracarotid injection · blood-brain barrier | VD | Open |
| 2 | 0.018 %/g | Comparable | Intravenous injection · blood-brain barrier | % injected dose | Open |
| 3 | 1.09 μL/g/min | Comparable | Intravenous injection · blood-brain barrier | PS | Open |
| 4 | Observation raw_value: 0.00815 ml/g; result: 0.00815 ml/g; transport_type: Permeability | Reported | NA · NA · NA · blood-brain barrier | Route: Intracarotid injection · Permeability | Open |
| 5 | Observation raw_value: 0.018 %/g; result: 0.018 %/g; transport_type: Permeability | Reported | NA · NA · NA · blood-brain barrier | Route: Intravenous · Permeability | Open |
| 6 | Observation raw_value: 1.09 μL/(g x min); result: 1.09 μL/(g x min); transport_type: Permeability | Reported | NA · NA · NA · blood-brain barrier | Route: Intravenous · Permeability | Open |
| 7 | Observation transport_type: Permeability | Reported | NA · NA · NA · blood-brain barrier | Route: Peripheral administration · Permeability | Open |
cell monolayer
barrier evidence
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1 days 86400 seconds | Comparable | HPLC and LC/ITMS · Bacterial strain B-9 cell culture | Dose/window: 1mg/mL · Time: Room Temperature · Hydolytic activity of bacterial strain B-9 · in vitro | Open |
| 2 | 6.78 minutes 406.8 seconds | Comparable | Radioimmunoassay · Intravenous injection of oxytocin in normal mares | Dose/window: 180mg · Time: 60 minutes · Blood protease · in vivo | Open |
| 3 | 6.78 minutes 406.8 seconds | Comparable | Radioimmunoassay · Intravenous injection of oxytocin in normal mares | Dose/window: 90mg · Time: 60 minutes · Blood protease · in vivo | Open |
The identity reference does not expose a sequence string.
CYIQNCPLG
CYIQNCPLG
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.